← FDA DRUG APPROVALS

FDA NDA · NDA009115

SERPASIL

Sponsor: NOVARTIS

APPLICATION
NDA009115
TYPE
NDA
ORIGINAL APPROVAL
1955-08-12
LATEST ACTION
1955-08-12
ROUTE
ORAL
DOSAGE FORM
ELIXIR, TABLET
MARKETING STATUS
Discontinued

Products

SERPASILDiscontinued
RESERPINE 0.2MG/4ML · ELIXIR · ORAL
SERPASILDiscontinued
RESERPINE 0.25MG · TABLET · ORAL
SERPASILDiscontinued
RESERPINE 0.1MG · TABLET · ORAL
SERPASILDiscontinued
RESERPINE 1MG · TABLET · ORAL

Approval history

1955-08-12Type 2 - New Active Ingredient · Original · priorityAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →